New Delhi: Investing in Initial Public Offerings (IPOs) can be risky, but for some, it can also be incredibly rewarding. Namita Thapar, a well-known entrepreneur from Shark Tank, has experienced massive success by investing in Emcure Pharmaceuticals. Her investment has yielded a staggering 293 times return, turning heads in the investment community. Namita Thapars journey with Emcure Pharmaceuticals is a remarkable one. She is one of the key promoters of the company and holds a significant number of shares.Namita owns 63,39,800 shares, which represent 3.5 percent of the company. Initially, these shares were valued at Rs 2.18 crore. As the company prepares for its IPO, Namitas investment has grown substantially.How did she earn 293 times returnMany wonder how Namita managed to earn such an extraordinary return even before Emcure Pharmaceuticals IPO. The answer lies in her strategic investment and timing. By being one of the early promoters, she was able to acquire shares at a much lower price. As the companys value increased over time, so did the worth of her shares.Selling shares ahead of IPOWith Emcure Pharmaceuticals IPO scheduled for Wednesday, July 3, Namita has decided to sell a portion of her shares. She plans to sell 12,68,600 equity shares at a price range of Rs 960-1008 per share. This move will allow her to realize a significant return on her investment.Remaining investment worth croresEven after selling some of her shares, Namita Thapar will still hold a substantial stake in Emcure Pharmaceuticals. After the sale, she will retain 50,71,200 shares, which are expected to be worth Rs 511.18 crore.IPO detailsEmcure Pharmaceuticals IPO aims to raise Rs 1952 crore and will close on Thursday, July 5, 2024. The company, founded in May 1982, has grown significantly over the years, attracting prominent investors like Namita Thapar. Her involvement since the companys inception highlights her long-term commitment and belief in its success.Other promoters success storiesNamita Thapar is not the only promoter enjoying substantial returns from Emcure Pharmaceuticals. Satish Ramlal Mehta, another major promoter, holds 7,58,16,748 shares, representing 41.8 percent of the company. His investment has yielded an impressive 989 times return. Similarly, Pushpa Rajnikant Mehta, with a 2.39 percent stake, has seen her investment grow by 25,200 times.
